<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588235</url>
  </required_header>
  <id_info>
    <org_study_id>TCFA-OCT XIJING01</org_study_id>
    <nct_id>NCT02588235</nct_id>
  </id_info>
  <brief_title>Ezetimibe and Atorvastatin Therapy on TCFA</brief_title>
  <official_title>Impact of Combined Ezetimibe and Atorvastatin Therapy on Coronary Thin-cap Fibroatheroma As Assessed by Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After successful coronary angiography and OCT examination, patients with TCFAs in
      non-culprit, mild-to-moderate stenotic lesions will be enrolled. Then, they will be randomly
      assigned in a 1:1 ratio to receive either atorvastatin (20 mg/day) alone or atorvastatin (20
      mg/day）plus ezetimibe（10 mg/day）by envelope method. Angiographic and OCT follow-up will be
      scheduled for the target vessel after 12 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized , controlled, open-label, single-center study to evaluate
      the effect of ezetimibe added to atorvastatin on coronary thin-cap fibroatheroma(TCFA). After
      successful coronary angiography and OCT examination, patients with TCFAs in non-culprit,
      mild-to-moderate stenotic lesions will be enrolled. Then, they will be randomly assigned in a
      1:1 ratio to receive either atorvastatin (20 mg/day) alone or atorvastatin (20 mg/day）plus
      ezetimibe（10 mg/day）by envelope method.

      Angiographic and OCT follow-up will be scheduled for the target vessel after 12 months.The
      primary efficacy endpoint is the change in minimum fibrous cap thickness measured by OCT from
      baseline to follow-up.The secondary endpoints include absolute and percent changes in the
      lipid, glycemic, and inflammatory profile. Then, changes of these indicators above will be
      compared respectively in diabetic and non-diabetic patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>minimum fibrous cap thickness</measure>
    <time_frame>12months</time_frame>
    <description>The primary efficacy endpoint is the change in minimum fibrous cap thickness measured by OCT from baseline to follow-up.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Ezetimibe and Atorvastatin Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin (20 mg/day）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe and Atorvastatin</intervention_name>
    <description>atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）</description>
    <arm_group_label>Ezetimibe and Atorvastatin Therapy</arm_group_label>
    <other_name>Ezetrol and lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>atorvastatin (20 mg/day）</description>
    <arm_group_label>Atorvastatin Therapy</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.stable angina or acute coronary syndrome 2.18-80 years old 3.hypercholesterolemia :total
        cholesterol level &gt;220 mg/dl (5.7mmol/L) and/or LDL-C level &gt;140 mg/dl(3.6mmol/L), or
        previously receiving statins therapy 4. the target vessel for OCT interrogation has not
        undergone angioplasty and has angiographic diameter stenosis from 25% to 75% 5.There are
        TCFAs in non-culprit, mild-to-moderate stenotic lesions above

        Exclusion Criteria:

          1. administration of lipid-lowering drugs other than statins before enrollment

          2. significant stenotic lesions in all coronary vessels

          3. severe congestive heart failure (New York Heart Association class IV) ,or left
             ventricular ejection fraction＜35%

          4. more than 3 times of the upper limit of normal (ULN) in the creatine kinase (CK) and
             the transaminase level before enrollment and no relation with myocardial infarction

          5. renal failure (serum creatinine＞2.0 mg/dL）

          6. hypersensitivity to x-ray contrast media, statin，clopidogrel or ezetimibe

          7. Others: terminal stage cancer,a positive pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Li, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dongdong Sun, M.D., Ph.D.</last_name>
    <phone>86 29 84775183</phone>
    <email>51483696@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongdong Sun, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>sunddong</investigator_full_name>
    <investigator_title>Attending</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

